{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:28:16Z","timestamp":1793978896633,"version":"4.8.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology Cardiovascular Risk and Prevention"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ijcrp.2026.200681","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T23:36:58Z","timestamp":1784072218000},"page":"200681","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Combination GLP-1 receptor agonist and SGLT2 inhibitor therapy versus GLP-1 receptor agonist monotherapy on arrhythmia outcomes in non-diabetic obese patients: A real-world time-dependent analysis"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8966-2711","authenticated-orcid":false,"given":"George A.","family":"Blankson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene A.","family":"Acheampong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham K.","family":"Carboo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis D.","family":"Kumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Amoah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdi","family":"Nawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Nii-Ashie Djanie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Prempeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adama","family":"Seidu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richmond K.E.","family":"Buckner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.ijcrp.2026.200681_bib1","first-page":"2362","article-title":"Obesity and the risk of incident atrial fibrillation: a systematic review and meta-analysis","volume":"66","author":"Wong","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.ijcrp.2026.200681_bib2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.pcad.2018.07.003","article-title":"An overview and update on obesity and the obesity paradox in cardiovascular diseases","volume":"61","author":"Elagizi","year":"2018","journal-title":"Prog. Cardiovasc. Dis."},{"issue":"4","key":"10.1016\/j.ijcrp.2026.200681_bib3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER)","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.ijcrp.2026.200681_bib4","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes (EMPA-REG OUTCOME)","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.ijcrp.2026.200681_bib5","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction (DAPA-HF)","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"10193","key":"10.1016\/j.ijcrp.2026.200681_bib6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND)","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ijcrp.2026.200681_bib7","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity (STEP 1)","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcrp.2026.200681_bib8","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT)","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.ijcrp.2026.200681_bib9","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease (DAPA-CKD)","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.ijcrp.2026.200681_bib10","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with preserved ejection fraction (EMPEROR-Preserved)","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcrp.2026.200681_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.910256","article-title":"Effects of GLP-1 receptor agonists on arrhythmias and their subtypes in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"13","author":"Wei","year":"2022","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ijcrp.2026.200681_bib12","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.15420\/cfr.2024.05","article-title":"Effects of glucagon-like peptide-1 receptor agonists on cardiac function, exercise capacity and quality of life","volume":"10","author":"Shchendrygina","year":"2024","journal-title":"Card. Fail. Rev."},{"key":"10.1016\/j.ijcrp.2026.200681_bib13","article-title":"Effects of GLP-1 agonists on mortality and arrhythmias in patients with type II diabetes","volume":"47","author":"Al-Sadawi","year":"2023","journal-title":"Ann. Chir. Thorac. Cardio-Vasc"},{"key":"10.1016\/j.ijcrp.2026.200681_bib14","doi-asserted-by":"crossref","DOI":"10.1111\/eci.14292","article-title":"Glucagon-like peptide-1 receptor agonist semaglutide reduces atrial fibrillation incidence: a systematic review and meta-analysis","volume":"54","author":"Saglietto","year":"2024","journal-title":"Eur. J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.ijcrp.2026.200681_bib15","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-020-01105-5","article-title":"SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review and mata-analysis of 16 randomized controlled trials","volume":"19","author":"Li","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ijcrp.2026.200681_bib16","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12933-024-02137-x","article-title":"Effect of SGLT-2 inhibitors on arrhythmia events: insight from an updated secondary analysis of >80,000 patients (the SGLT2i\u2014Arrhythmias and sudden cardiac death)","volume":"23","author":"Liao","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"issue":"2","key":"10.1016\/j.ijcrp.2026.200681_bib17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3390\/jpm12020271","article-title":"Clinical observation of SGLT2 inhibitor therapy for cardiac arrhythmia and related cardiovascular disease in diabetic patients with controlled hypertension","volume":"12","author":"Jhuo","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.ijcrp.2026.200681_bib18","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/ehjcvp\/pvaf040","article-title":"Prevention of atrial fibrillation with SGLT2 inhibitors across the spectrum of cardiovascular disorders: a meta-analysis of randomized controlled trials","volume":"11","author":"Fedele","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"issue":"12","key":"10.1016\/j.ijcrp.2026.200681_bib19","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","volume":"4","author":"Fr\u00edas","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"10","key":"10.1016\/j.ijcrp.2026.200681_bib20","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/dom.12982","article-title":"Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor","volume":"19","author":"DeFronzo","year":"2017","journal-title":"Diabetes Obes. Metabol."},{"issue":"10","key":"10.1016\/j.ijcrp.2026.200681_bib21","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"issue":"18","key":"10.1016\/j.ijcrp.2026.200681_bib22","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis","volume":"146","author":"Packer","year":"2022","journal-title":"Circulation"},{"issue":"25","key":"10.1016\/j.ijcrp.2026.200681_bib23","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1161\/CIRCULATIONAHA.119.045561","article-title":"Role of deranged energy deprivation signaling in the pathogenesis of cardiac and renal disease in states of perceived nutrient overabundance","volume":"141","author":"Packer","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ijcrp.2026.200681_bib24","doi-asserted-by":"crossref","DOI":"10.1007\/s10840-026-02274-1","article-title":"The impact of sodium glucose cotransporter-2 inhibitors on ventricular arrhythmia in patients with implantable cardioverter-defibrillators: a meta analysis","author":"Jha","year":"2026","journal-title":"J. Intervent. Card Electrophysiol."},{"issue":"10166","key":"10.1016\/j.ijcrp.2026.200681_bib25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ijcrp.2026.200681_bib26","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol."}],"container-title":["International Journal of Cardiology Cardiovascular Risk and Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S277248752600111X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S277248752600111X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:04:29Z","timestamp":1793977469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S277248752600111X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":26,"alternative-id":["S277248752600111X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcrp.2026.200681","relation":{},"ISSN":["2772-4875"],"issn-type":[{"value":"2772-4875","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination GLP-1 receptor agonist and SGLT2 inhibitor therapy versus GLP-1 receptor agonist monotherapy on arrhythmia outcomes in non-diabetic obese patients: A real-world time-dependent analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology Cardiovascular Risk and Prevention","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcrp.2026.200681","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"200681"}}